Enilospirone (CERM-3726) is essentially a central stimulant. At low doses (100 mg) it may improve performance and at higher doses it may lead to disturbance of sleep continuity. These effects may not involve DA mechanisms, though changes such as those in REM sleep with chronic ingestion could involve the noradrenergic pathway. The property of the drug, even at low doses, to oppose the deterioration in performance associated with tests of prolonged duration is likely to be due to a mild alerting effect.

Butaverine is a fatty acid ester with antispasmodic activity which was under development for treatment urinary incontinence

Nanofin is a ganglion blocker alkaloid having nicotinic acetylcholine receptor antagonist action. It has an antihypertensive effect used for mild to moderate hypertension. It was also used for the treatment of eczema and neurodermatitis.

Colterol is a beta-2 adrenoreceptor agonist. Bitolterol, a diester prodrug of colterol, was marketed by Elan Pharmaceuticals for the treatment of reversible bronchospasm associated with asthma or chronic obstructive pulmonary diseases.

Phenadoxone hydrochloride is one of some forty amino-ketones and amino-esters related to amidone. The compound is a very potent analgesic for the rat; by the subcutaneous route it is more active than either morphine or amidone. In spite of this its acute toxicity to mice is lower than that of amidone and its therapeutic index is therefore correspondingly higher, giving a wider margin of safety. Side effects in dogs, such as narcosis, sedation, and general depression, were much less with phenadoxone than with amidone or morphine. Nausea and vomiting did not occur after phenadoxone in non-tolerant dogs. Clinical results show that for relieving certain types of pain in human subjects it is a potent analgesic that compares favorably with morphine and amidone. At therapeutic dose levels undesirable pharmacological effects, such as cardiac depression and vasomotor disturbance, are absent, and it is only at extremely high dose levels that untoward effects occur. However, the drug has a strong respiratory depressant action when given in high doses; it should be used with special caution if injected intravenously.

Metostilenol was developed as an antidepressant. However, it has never been marketed.

ISOPROFEN is an anti-inflammatory agent with analgesic and antipyretic properties. Its anti-inflammatory potency is greater than that of phenylbutazone but lower than that of indomethacin. Its antipyretic action can be explained by an effect of this substance on the metabolism of arachidonic acid in the brain.

Pancopride (LAS 30451) is a 5-hydroxytryptamine 3 receptor antagonist and was developed against cytotoxic drug-induced emesis. Pancopride was studied in clinical trials in patients treated with highly emetogenic chemotherapy. It was found a combination of Pancopride with dexamethasone was the most effective against chemotherapy-induced vomiting. However, information about the further development of this drug is not available.

Pardoprunox is a partial D2/3 dopamine receptor agonist and full 5-HT1A serotonin receptor agonist. Partial D(2/3) dopamine (DA) receptor agonists provide a novel approach to the treatment of the motor symptoms of Parkinson's disease that may avoid common dopaminergic side effects, including dyskinesia and psychosis. Pardoprunox passed phase III clinical trial for the treatment of Parkinson's disease.

Febuverine is a spasmolytic and local anesthetic.